CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
DERBB3OverexpressionPredictiveSupportsSensitivity/ResponseCancerSelumetinib,AfatinibSun et al., 2014
BMMP2SERUM LEVELSPredictiveSupportsSensitivity/ResponseInflammatory Breast CarcinomaBevacizumabTabouret et al., 2016
BMMP9SERUM LEVELSPredictiveSupportsResistanceInflammatory Breast CarcinomaBevacizumabTabouret et al., 2016
DKRASG12CPredictiveSupportsSensitivity/ResponseCancerEpidermal Growth Factor Receptor Tyrosine Kinase Inhibitor,ARS-853Patricelli et al., 2016
BKRASG13DPredictiveSupportsResistanceColorectal CancerCetuximabSchirripa et al., 2015
DKRASMutationPredictiveSupportsSensitivity/ResponseCancerAZD5438Costa-Cabral et al., 2016
DMIR218-1UNDEREXPRESSIONPrognosticSupportsPoor OutcomePancreatic CancerLi et al., 2015
CMETExon 14 Skipping MutationPredictiveSupportsSensitivity/ResponseLung AdenocarcinomaCrizotinibAwad et al., 2016
CMETExon 14 Skipping MutationPredictiveSupportsSensitivity/ResponseLung AdenocarcinomaCapmatinibFrampton et al., 2015
BKRASExon 2 MutationPredictiveSupportsResistanceColorectal CancerEpidermal Growth Factor Receptor Tyrosine Kinase InhibitorAzuara et al., 2016
BGNA11Q209PredictiveDoes Not SupportSensitivity/ResponseUveal MelanomaSelumetinibCarvajal et al., 2014
BGNAQQ209PredictiveDoes Not SupportSensitivity/ResponseUveal MelanomaSelumetinibCarvajal et al., 2014
BKRASG12DPrognosticSupportsBetter OutcomeColorectal CancerModest et al., 2012
BKRASG12CPredictiveSupportsResistanceColorectal CancerErlotinib,GefitinibFiala et al., 2013
BKRASG12CPrognosticSupportsPoor OutcomeLung Non-small Cell CarcinomaIhle et al., 2012
BKRASMutationPredictiveDoes Not SupportSensitivity/ResponseLung AdenocarcinomaSalirasibRiely et al., 2011
BKITMutationPredictiveSupportsSensitivity/ResponseMelanomaImatinibGuo et al., 2011
BKITExon 9 MutationPredictiveSupportsSensitivity/ResponseGastrointestinal Stromal TumorSunitinibRutkowski et al., 2012
CKITExon 11 MutationPredictiveSupportsSensitivity/ResponseMelanomaSunitinibMinor et al., 2012
DNRASMutationPredictiveSupportsSensitivity/ResponseCancerMetformin,TrametinibVujic et al., 2015
BPTENDeletionPredictiveSupportsSensitivity/ResponseProstate CancerEverolimusTempleton et al., 2013
BPTENMutationPredictiveDoes Not SupportSensitivity/ResponseEndometrial CarcinomaEverolimusTrédan et al., 2013
DBAP1MutationPredictiveSupportsSensitivity/ResponseUveal MelanomaTrichostatin A,Valproic Acid,Panobinostat,VorinostatLandreville et al., 2012
DFGFR2MutationPredictiveSupportsSensitivity/ResponseEndometrial CancerPonatinibKim et al., 2016
BDNMT3AMutationPrognosticSupportsPoor OutcomeMyelodysplastic SyndromeWalter et al., 2011
Bv::ALKFusionPredictiveSupportsSensitivity/ResponseInflammatory Myofibroblastic TumorCrizotinibMossé et al., 2013
CEML4::ALKe6::e20PredictiveSupportsSensitivity/ResponseCancerCrizotinibChung et al., 2014
DFGFR1AmplificationPredictiveSupportsSensitivity/ResponseEwing Sarcoma Of BonePonatinibAgelopoulos et al., 2015
DROS1G2032R AND CD74::ROS1 FusionPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaCabozantinib,ForetinibDavare et al., 2015
DROS1G2032R AND CD74::ROS1 FusionPredictiveSupportsResistanceLung Non-small Cell CarcinomaCrizotinib,Brigatinib,Ceritinib,AZD3463Davare et al., 2015
DROS1G2032R AND v::ROS1 FusionPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaLorlatinibZou et al., 2015
DROS1L2026M AND CD74::ROS1 FusionPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaLorlatinibZou et al., 2015
CROS1G2032R AND CD74::ROS1 FusionPredictiveSupportsResistanceLung Non-small Cell CarcinomaCrizotinibSong et al., 2015
DROS1L2155S AND CD74::ROS1 FusionPredictiveSupportsResistanceLung Non-small Cell CarcinomaForetinib,Crizotinib,ALK Inhibitor TAE684Song et al., 2015
CCLTC::ALKFusionPrognosticSupportsPoor OutcomeDiffuse Large B-cell LymphomaLaurent et al., 2009
CCLTC::ALKFusionPredictiveSupportsSensitivity/ResponseDiffuse Large B-cell LymphomaCrizotinibLi et al., 2015
EEML4::ALKe2::e20PredictiveSupportsSensitivity/ResponseRenal Cell CarcinomaSugawara et al., 2012
DBRAFL485_P490delPredictiveSupportsSensitivity/ResponseCancerPan-RAF Inhibitor LY3009120Chen et al., 2016
CALKF1174LPredictiveDoes Not SupportSensitivity/ResponseNeuroblastomaCrizotinibMossé et al., 2013
Bv::ALKFusionPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaAlectinibSeto et al., 2013
Cv::ALKFusionPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaAlectinibYoshida et al., 2016
BCD274ExpressionPrognosticSupportsPoor OutcomePapillary Thyroid CarcinomaChowdhury et al., 2016
BCD274ExpressionPrognosticSupportsBetter OutcomeStomach CarcinomaBöger et al., 2016
CDUX4::vFusionPrognosticSupportsBetter OutcomeAcute Lymphoblastic LeukemiaYasuda et al., 2016
BB4GALT1OverexpressionPrognosticSupportsPoor OutcomeRenal Cell CarcinomaXie et al., 2016
DALKI1171PredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaALK Inhibitor TAE684Katayama et al., 2014
DEML4::ALKFusion AND ALK V1180LPredictiveSupportsResistanceLung Non-small Cell CarcinomaAlectinibKatayama et al., 2014
DALKI1171PredictiveSupportsResistanceLung Non-small Cell CarcinomaCrizotinibKatayama et al., 2014
DEML4::ALKFusion AND ALK V1180LPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaCeritinibKatayama et al., 2014
DEML4::ALKFusion AND ALK V1180LPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaALK Inhibitor TAE684Katayama et al., 2014
Page 34 of 96
PreviousNext